ABSTRACT

The use of neuropharmacologic interventions to modulate impairment in persons with acquired brain injury (ABI) has become a mainstay of good neurorehabilitation care. Unfortunately, there has been a historical dearth of consolidated information on the pharmacologic approaches and their rationale relative to their application in this subset of neurological patients. In fact, there is likely to be better consensus among physicians in the field of neurorehabilitation regarding the psychopharmacologic management of ABI-related neurobehavioral impairments than there is for neuropharmacologic management, with the exceptions of pharmacologic approaches to epilepsy and spasticity management.